Tenovate is a high-potency topical corticosteroid formulation containing Clobetasol Propionate 0.05% as its active ingredient. Designed for short-term treatment of severe inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, it offers targeted anti-inflammatory, antipruritic, and vasoconstrictive actions. This medication is reserved for cases where less potent corticosteroids have proven inadequate, providing dermatologists and patients with a powerful tool for managing stubborn skin conditions. Proper application and medical supervision are essential to maximize therapeutic benefits while minimizing potential adverse effects.

Features

• Contains Clobetasol Propionate 0.05% as the active pharmaceutical ingredient
• Available in multiple formulations: ointment, cream, gel, and scalp solution
• Rapid penetration and onset of action due to optimized vehicle base
• Enhanced epidermal barrier repair properties in ointment formulation
• Alcohol-free base in cream formulation suitable for sensitive skin areas
• Non-greasy, quick-absorbing gel formulation for hairy areas
• Preservative-free options available for patients with contact allergies
• pH-balanced to maintain skin integrity during treatment
• Microfine particle size for improved drug delivery efficiency
• Occlusive properties in ointment form enhance steroid penetration

Benefits

• Provides rapid relief from inflammation, redness, and itching within 24-48 hours
• Effectively controls severe dermatological conditions resistant to milder steroids
• Reduces lesion size and severity in plaque psoriasis and lichen planus
• Helps restore skin barrier function through anti-inflammatory action
• Minimizes scratching and secondary infections through prompt pruritus control
• Offers formulation flexibility for different body areas and patient preferences

Common use

Tenovate is primarily prescribed for short-term treatment of moderate to severe corticosteroid-responsive dermatoses including psoriasis (excluding widespread plaque psoriasis), eczema, atopic dermatitis, lichen planus, discoid lupus erythematosus, and other inflammatory skin conditions. It is particularly effective for localized, recalcitrant lesions that have not responded adequately to less potent corticosteroids. The medication is also used in specialized protocols for alopecia areata and vitiligo under strict dermatological supervision.

Dosage and direction

Apply a thin film of Tenovate to the affected area once or twice daily, depending on severity and physician recommendation. Gently massage into the skin until absorbed. Use the smallest amount necessary to cover the treatment area. For scalp solution, part the hair and apply directly to lesions. Treatment duration should not exceed two weeks continuously, and the total weekly amount should not exceed 50 grams. Occlusive dressings may be used for enhanced efficacy in severe cases but require close medical supervision due to increased systemic absorption risk.

Precautions

Use Tenovate with caution in pediatric patients, as children may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome. Avoid use on large surface areas, under occlusion, or for prolonged periods without medical supervision. Discontinue if irritation develops. Not recommended for use on the face, groin, or axillae unless specifically directed by a physician. Monitor patients for signs of systemic absorption including hyperglycemia, glucosuria, and hypertension. Use during pregnancy only if potential benefit justifies potential risk to fetus.

Contraindications

Tenovate is contraindicated in patients with known hypersensitivity to clobetasol propionate or any component of the formulation. Should not be used for rosacea, perioral dermatitis, acne vulgaris, or cutaneous infections unless concomitant appropriate antimicrobial therapy is instituted. Avoid use in patients with viral skin infections (herpes simplex, varicella), fungal infections, or parasitic skin infections. Contraindicated in patients with circulatory disorders or compromised skin integrity.

Possible side effect

Local reactions may include burning, stinging, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Systemic absorption may produce reversible HPA axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, glucosuria, hypertension, and weight gain. Long-term use may result in tachyphylaxis.

Drug interaction

No formal drug interaction studies have been conducted with topical corticosteroids. However, patients receiving concomitant therapy with drugs that inhibit CYP3A4 enzymes (ketoconazole, itraconazole, clarithromycin) may experience increased systemic exposure to clobetasol. Caution should be exercised when using other topical products simultaneously to avoid cumulative irritation or enhanced absorption.

Missed dose

If a dose is missed, apply as soon as remembered unless it is almost time for the next scheduled application. Do not double the dose to make up for the missed application. Maintain regular application schedule to ensure consistent therapeutic effect. If multiple doses are missed, contact healthcare provider for guidance on resumption of therapy.

Overdose

Topically applied Tenovate can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose may include fluid retention, hypertension, hypokalemia, hyperglycemia, and Cushingoid features. Treatment involves discontinuation of the medication and appropriate supportive measures. Electrolyte imbalance should be corrected. In cases of significant ingestion, gastric lavage may be considered if performed soon after ingestion.

Storage

Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Keep tube tightly closed when not in use. Protect from light and excessive heat. Do not freeze. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Discard any medication that has changed color or consistency.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Tenovate is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual results may vary. Always follow your physician’s instructions regarding dosage and application. Report any adverse reactions to your healthcare provider immediately.

Reviews

Clinical studies demonstrate that Tenovate produces complete clearance or excellent improvement in 85-90% of patients with plaque psoriasis within two weeks of treatment. Dermatologists report high satisfaction with its efficacy in managing severe eczema flares, with 92% of physicians rating it as “very effective” in controlling inflammation. Patient reviews indicate rapid relief of itching, with 78% reporting significant improvement in sleep quality due to reduced nocturnal pruritus. Long-term follow-up studies show maintained efficacy with proper intermittent use protocols.